Company / Accounts Receivable
UroGen Pharma Ltd. Accounts Receivable History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$33.1M
FY2025
5-year range
$11.7M / $33.1M
FY2021-FY2025
Trend
+62.9%
vs FY2024
Sector context
#80 of 113
Health Care
What the data says
At $33M, UroGen Pharma Ltd.'s accounts receivable ranks #80 of 113 in the Health Care sector. Accounts Receivable has increased for 5 consecutive years, from $7M in FY2020 to $33M in FY2025.
Based on SEC 10-K filings.
$33M in FY2025 with a 5-year CAGR of +36.2%.
Improved from $15M to $33M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +37.6%
- 5-Year CAGR
- +36.2%
- 10-Year CAGR
- -
Sector benchmark
#80 of 113 in Health CareTop 71% of 113This company $33.1M Sector average $1.1B
▼
-97.1% below sector average
Key checks
Key Insights
- UroGen Pharma Ltd.'s accounts receivable has grown for 5 consecutive years.
- 5-year CAGR of +36.2%, indicating consistent growth.
- In FY2025, accounts receivable increased 62.9% year-over-year.
- Ranks #80 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $33.1M | +62.9% |
| FY2024 | $20.3M | +31.5% |
| FY2023 | $15.4M | +21.6% |
| FY2022 | $12.7M | +8.4% |
| FY2021 | $11.7M | +66.3% |
| FY2020 | $7.0M | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026